Versant Venture Capital VI, L.P. 4
Accession 0001193125-25-211363
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 4:23 PM ET
Size
29.9 KB
Accession
0001193125-25-211363
Insider Transaction Report
- Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total
- 842,162(indirect: See Footnote)
Common Stock
- Sale
Common Stock
2025-09-18$43.00/sh−20,148$866,441→ 856,289 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$41.59/sh−49,479$2,057,871→ 1,224,718 total - Sale
Common Stock
2025-09-18$43.30/sh−132$5,716→ 856,157 total(indirect: See Footnote) - Sale
Common Stock
2025-09-18$43.00/sh−40,907$1,759,156→ 1,183,811 total - Sale
Common Stock
2025-09-18$43.30/sh−268$11,604→ 1,183,543 total - Sale
Common Stock
2025-09-18$41.59/sh−24,370$1,013,568→ 876,437 total(indirect: See Footnote)
- 842,162(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- [F3]These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
- [F4]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
LENZ Therapeutics, Inc.
CIK 0001815776
Related Parties
1- filerCIK 0001687880
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 4:23 PM ET
- Size
- 29.9 KB